Recent News

• 03.20.2025 - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
• 03.20.2025 - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
• 03.20.2025 - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
• 11.25.2024 - NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
• 11.25.2024 - NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
• 11.25.2024 - NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
• 11.11.2024 - NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
• 11.11.2024 - NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Recent Filings

• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.18.2025 - EX-99.1 EX-99.1
• 03.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.25.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.25.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.12.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]